Delflex shortage — US supply status & alternatives

Delflex

—

In supply · Australia

DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange Set for Intraperiton

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Therapeutic category
Active ingredient (INN)	Delflex
Brand names	DELFLEX, Dextrose Peritoneal Dialysis Solution with attached stay-safe Exchange Set for Intraperiton

Controlled substance	No

Marketing-authorisation holders	Fresenius Medical Care de Mexico, S.A. de C.V., FRESENIUS MEDICAL CARE NORTH AMERICA, FRESENIUS USA MANUFACTURING INC, FRESENIUS MEDICAL CARE CANADA INC

Registrations on file	15

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

FDA MedWatch · 19h ago

High

Recalls official enforcement reports

🇺🇸

Delflex

Fresenius Medical Care Holdings, Inc. · Apr 2026

Class IIdetails ↗

🇺🇸

Delflex

Fresenius Medical Care Holdings, Inc. · Apr 2026

Class IIdetails ↗

Verified timeline regulator events

🇺🇸 6 Apr 2026

high reported

Sources official regulators

🇺🇸

FDA MedWatch

verified 19h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders15 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
Delflex	18.4; 1.5; 5.08; 538; 448mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL	solution	🇺🇸 US	Fresenius Medical Care de Mexico, S.A. de C.V.	Active
Delflex	18.4; 2.5; 5.08; 538; 448mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL	solution	🇺🇸 US	Fresenius Medical Care de Mexico, S.A. de C.V.	Active
Delflex	18.4; 4.25; 5.08; 538; 448mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL	solution	🇺🇸 US	Fresenius Medical Care de Mexico, S.A. de C.V.	Active
DELFLEX	25.7; 1.5; 15.2; 567; 392mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL	solution	🇺🇸 US	FRESENIUS MEDICAL CARE NORTH AMERICA	Active
DELFLEX	25.7; 2.5; 15.2; 567; 392mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL	solution	🇺🇸 US	FRESENIUS MEDICAL CARE NORTH AMERICA	Active
Delflex A Periton.Dial.Soln. W.2.5% Dextrose	2.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex A Periton.Dial.Soln.W.4.25% Dextrose	4.25%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex A Perit.Dial.Soln.W	1.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex A Perit.Dial.Soln.W	2.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex A Perit.Dial.Soln W	4.25%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex Perit.Dial.Sol	1.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex Perit.Dial.Sol	2.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex Perit.Dial.Sol	4.25%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex A Periton.Dial.Soln.W.1.5% Dextrose	1.5%	solution	🇨🇦 CA	FRESENIUS USA MANUFACTURING INC	Active
Delflex Peritoneal Dialysis Solution With 0.5% Dextrose	0.5%	liquid	🇨🇦 CA	FRESENIUS MEDICAL CARE CANADA INC	Cancelled

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.